Pharmaceuticals & Biotech Belgian Community

Our community narratives are driven by numbers and valuation.

Value any stock for free in seconds

Get alerts and valuation updates

Participate in discussions

WA

Analyst Price Target

Consensus Narrative from 18 Analysts

BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology

Key Takeaways UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets. Expansion in therapeutic areas like Alzheimer's and dermatology aims to meet unmet needs and boost profitability.

€209.22

FV

6.8% undervalued

11.27%

Revenue growth p.a.

1

0

2

2 days ago